INSR
MOLECULAR TARGETinsulin receptor
INSR (insulin receptor) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting INSR
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | osimertinib | 5.03 | 152 |
| 2 | lapatinib | 4.84 | 126 |
| 3 | foretinib | 4.34 | 76 |
| 4 | tozasertib | 4.33 | 75 |
| 5 | ceritinib | 4.19 | 65 |
| 6 | brigatinib | 3.81 | 44 |
| 7 | neratinib | 3.66 | 38 |
| 8 | nintedanib | 3.61 | 36 |
| 9 | tae 684 | 3.43 | 30 |
| 10 | fedratinib | 3.40 | 29 |
| 11 | entrectinib | 3.18 | 23 |
| 12 | purvalanola | 3.18 | 23 |
| 13 | lestaurtinib | 3.04 | 20 |
| 14 | r 406 | 2.83 | 16 |
| 15 | infigratinib | 2.77 | 15 |
| 16 | pha 665752 | 2.71 | 14 |
| 17 | kw 2449 | 2.64 | 13 |
| 18 | linsitinib | 2.64 | 13 |
| 19 | ast 487 | 2.56 | 12 |
| 20 | aloisine a | 2.40 | 10 |
| 21 | bms 754807 | 2.30 | 9 |
| 22 | su 014813 | 2.20 | 8 |
| 23 | asp 3026 | 2.08 | 7 |
| 24 | purvalanol b | 2.08 | 7 |
| 25 | Crizotinib | 1.95 | 6 |
| 26 | maleimide | 1.95 | 6 |
| 27 | bastadin 7 | 1.95 | 6 |
| 28 | pf 03814735 | 1.79 | 5 |
| 29 | osi 632 | 1.79 | 5 |
| 30 | Apigenin 5,7,4'-trihydroxy-flavone, | 1.39 | 3 |
| 31 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
| 32 | Sorafenib | 0.69 | 1 |
| 33 | sp600125 | 0.69 | 1 |
About INSR as a Drug Target
INSR (insulin receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented INSR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
INSR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.